Moreover, treatment with a CXCR3 antagonist or a CXCL10-neutralizing antibody reduced T-ALL adhesion, underscoring the role of CXCL10-CXCR3 signaling in mediating cell-cell adhesion. Here, CXCR3 is linked to acute lymphoblastic leukemia.